Zijian Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zijian Yang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Xiao Han
Department of Ophthalmology, Sunshine Rehabilitation Center, Tongji University School of Medicine, China
2 shared publicationsYing Chen
Department of Ophthalmology, Sunshine Rehabilitation Center, Tongji University School of Medicine, China
2 shared publications- Yisheng Zhong
Department of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2 shared publications Yuzhen Chen
Department of Ophthalmology, Sunshine Rehabilitation Center, Tongji University School of Medicine, China
2 shared publicationsHuan Yu
Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiaotong University, Shanghai, China
1 shared publicationHuimin Zhong
Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 15 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1689341
Correction: Comparative effectiveness of gamified binocular treatment versus conventional patching for amblyopia: a randomized clinical trial
Correction on: Chen Y, Chen Y, Han X, Yang Z. Comparative effectiveness of gamified binocular treatment versus conventional patching for amblyopia: a randomized clinical trial. Front Med (Lausanne). 2025;12:1560203. Published 2025 Jun 2. doi:10.3389/fmed.2025.1560203 Equal contribution statement Missing In the published article, Ying Chen and Yuzhen Chen were erroneously omitted as equal contributing authors. The corrected statement reads: 'Ying Chen and Yuzhen Chen contributed equally to this work and share first authorship.' The original version of this article has been updated.
- 15 September 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1689341
Open AccessCorrection: Comparative effectiveness of gamified binocular treatment versus conventional patching for amblyopia: a randomized clinical trial
Correction on: Chen Y, Chen Y, Han X, Yang Z. Comparative effectiveness of gamified binocular treatment versus conventional patching for amblyopia: a randomized clinical trial. Front Med (Lausanne). 2025;12:1560203. Published 2025 Jun 2. doi:10.3389/fmed.2025.1560203 Equal contribution statement Missing In the published article, Ying Chen and Yuzhen Chen were erroneously omitted as equal contributing authors. The corrected statement reads: 'Ying Chen and Yuzhen Chen contributed equally to this work and share first authorship.' The original version of this article has been updated.
- Open Access
- 2 June 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1560203
Comparative effectiveness of gamified binocular treatment versus conventional patching for amblyopia: a randomized clinical trial
Introduction: Amblyopia, a prevalent visual disorder in children, leads to deficits in visual acuity, stereoacuity, and daily functioning. Conventional treatments such as eye patching, often encounter adherence challenges and relapse, especially in younger patients. This study investigates the effectiveness of a home-based, gamified binocular therapy (GBT), compared with traditional patching.Methods: A randomized controlled trial was conducted with 42 participants aged 4–8 years diagnosed with amblyopia from Sunshine Rehabilitation Center, Shanghai. Participants were randomly assigned to the GBT (n = 20) or the patching group (n = 22). Visual acuity (VA) and stereoacuity improvements were assessed at baseline, 1, 3, and 6 months.Results: Both groups demonstrated significant VA and stereoacuity improvements from baseline at 1 month. GBT participants exhibited faster initial VA improvement, with significant gains at 1 month compared to patching (mean difference = 0.072 logarithm of the minimum angle of resolution[logMAR], p = 0.0029). By 6 months, both groups showed similar improvements in VA (GBT: 0.19 ± 0.10 logMAR; patching: 0.23 ± 0.16; p = 0.156) and stereoacuity (GBT: 0.95 ± 0.76 log arcseconds; patching: 0.82 ± 0.59; p = 0.712). No significant adverse events were reported in either group.Conclusion: The study indicates that GBT is as effective as patching in improving amblyopic visual outcomes among Chinese children 4 to 8 years of age. These findings suggest that gamified binocular therapy could play an important role in personalized amblyopia treatment, with further studies needed to confirm long-term effects across diverse populations.
- 2 June 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1560203
Open AccessComparative effectiveness of gamified binocular treatment versus conventional patching for amblyopia: a randomized clinical trial
Introduction: Amblyopia, a prevalent visual disorder in children, leads to deficits in visual acuity, stereoacuity, and daily functioning. Conventional treatments such as eye patching, often encounter adherence challenges and relapse, especially in younger patients. This study investigates the effectiveness of a home-based, gamified binocular therapy (GBT), compared with traditional patching.Methods: A randomized controlled trial was conducted with 42 participants aged 4–8 years diagnosed with amblyopia from Sunshine Rehabilitation Center, Shanghai. Participants were randomly assigned to the GBT (n = 20) or the patching group (n = 22). Visual acuity (VA) and stereoacuity improvements were assessed at baseline, 1, 3, and 6 months.Results: Both groups demonstrated significant VA and stereoacuity improvements from baseline at 1 month. GBT participants exhibited faster initial VA improvement, with significant gains at 1 month compared to patching (mean difference = 0.072 logarithm of the minimum angle of resolution[logMAR], p = 0.0029). By 6 months, both groups showed similar improvements in VA (GBT: 0.19 ± 0.10 logMAR; patching: 0.23 ± 0.16; p = 0.156) and stereoacuity (GBT: 0.95 ± 0.76 log arcseconds; patching: 0.82 ± 0.59; p = 0.712). No significant adverse events were reported in either group.Conclusion: The study indicates that GBT is as effective as patching in improving amblyopic visual outcomes among Chinese children 4 to 8 years of age. These findings suggest that gamified binocular therapy could play an important role in personalized amblyopia treatment, with further studies needed to confirm long-term effects across diverse populations.
- Open Access
- 8 May 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-13
MiR-146a reduces fibrosis after glaucoma filtration surgery in rats
Purpose: To explore the impact of microRNA 146a (miR-146a) and the underlying mechanisms in profibrotic changes following glaucoma filtering surgery (GFS) in rats and stimulation by transforming growth factor (TGF)-β1 in rat Tenon’s capsule fibroblasts. Methods: Cultured rat Tenon’s capsule fibroblasts were treated with TGF-β1 and analyzed with microarrays for mRNA profiling to validate miR-146a as the target. The Tenon’s capsule fibroblasts were then respectively treated with lentivirus-mediated transfection of miR-146a mimic or inhibitor following TGF-β1 stimulation in vitro, while GFS was performed in rat eyes with respective intraoperative administration of miR-146a, mitomycin C (MMC), or 5-fluorouracil (5-FU) in vivo. Profibrotic genes expression levels (fibronectin, collagen Iα, NF-KB, IL-1β, TNF-α, SMAD4, and α-smooth muscle actin) were determined through qPCR, Western blotting, immunofluorescence staining and/or histochemical analysis in vitro and in vivo. SMAD4 targeting siRNA was further used to treat the fibroblasts in combination with miR-146a intervention to confirm its role in underlying mechanisms. Results: Upregulation of miR-146a reduced the proliferation rate and profibrotic changes of rat Tenon’s capsule fibroblasts induced by TGF-β1 in vitro, and mitigated subconjunctival fibrosis to extend filtering blebs survival after GFS in vivo, where miR-146a decreased expression levels of NF-KB-SMAD4-related genes, such as fibronectin, collagen Iα, NF-KB, IL-1β, TNF-α, SMAD4, and α-smooth muscle actin(α-SMA). Additionally, SMAD4 is a key target gene in the process of miR-146a inhibiting fibrosis. Conclusions: MiR-146a effectively reduced TGF-β1-induced fibrosis in rat Tenon’s capsule fibroblasts in vitro and in vivo, potentially through the NF-KB-SMAD4 signaling pathway. MiR-146a shows promise as a novel therapeutic target for preventing fibrosis and improving the success rate of GFS.
- 8 May 2024
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 22 (1) , 1-13
Open AccessMiR-146a reduces fibrosis after glaucoma filtration surgery in rats
Purpose: To explore the impact of microRNA 146a (miR-146a) and the underlying mechanisms in profibrotic changes following glaucoma filtering surgery (GFS) in rats and stimulation by transforming growth factor (TGF)-β1 in rat Tenon’s capsule fibroblasts. Methods: Cultured rat Tenon’s capsule fibroblasts were treated with TGF-β1 and analyzed with microarrays for mRNA profiling to validate miR-146a as the target. The Tenon’s capsule fibroblasts were then respectively treated with lentivirus-mediated transfection of miR-146a mimic or inhibitor following TGF-β1 stimulation in vitro, while GFS was performed in rat eyes with respective intraoperative administration of miR-146a, mitomycin C (MMC), or 5-fluorouracil (5-FU) in vivo. Profibrotic genes expression levels (fibronectin, collagen Iα, NF-KB, IL-1β, TNF-α, SMAD4, and α-smooth muscle actin) were determined through qPCR, Western blotting, immunofluorescence staining and/or histochemical analysis in vitro and in vivo. SMAD4 targeting siRNA was further used to treat the fibroblasts in combination with miR-146a intervention to confirm its role in underlying mechanisms. Results: Upregulation of miR-146a reduced the proliferation rate and profibrotic changes of rat Tenon’s capsule fibroblasts induced by TGF-β1 in vitro, and mitigated subconjunctival fibrosis to extend filtering blebs survival after GFS in vivo, where miR-146a decreased expression levels of NF-KB-SMAD4-related genes, such as fibronectin, collagen Iα, NF-KB, IL-1β, TNF-α, SMAD4, and α-smooth muscle actin(α-SMA). Additionally, SMAD4 is a key target gene in the process of miR-146a inhibiting fibrosis. Conclusions: MiR-146a effectively reduced TGF-β1-induced fibrosis in rat Tenon’s capsule fibroblasts in vitro and in vivo, potentially through the NF-KB-SMAD4 signaling pathway. MiR-146a shows promise as a novel therapeutic target for preventing fibrosis and improving the success rate of GFS.
- Open Access
- 29 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16946
Inhibition of Ferroptosis Ameliorates Photoreceptor Degeneration in Experimental Diabetic Mice
Diabetic retinopathy (DR) is a leading cause of vision impairment in the working-age population worldwide. Various modes of photoreceptor cell death contribute to the development of DR, including apoptosis and autophagy. However, whether ferroptosis is involved in the pathogenesis of photoreceptor degeneration in DR is still unclear. High-glucose (HG)-stimulated 661W cells and diabetic mice models were used for in vitro and in vivo experiments, respectively. The levels of intracellular iron, glutathione (GSH), reactive oxygen species (ROS), lipid peroxidation (MDA), and ferroptosis-related proteins (GPX4, SLC7A11, ACSL4, FTH1, and NCOA4) were quantified to indicate ferroptosis. The effect of ferroptosis inhibition was also assessed. Our data showed the levels of iron, ROS, and MDA were enhanced and GSH concentration was reduced in HG-induced 661W cells and diabetic retinas. The expression of GPX4 and SLC7A11 was downregulated, while the expression of ACSL4, FTH1, and NCOA4 was upregulated in the 661W cells cultured under HG conditions and in the photoreceptor cells in diabetic mice. Furthermore, the administration of the ferroptosis inhibitor ferrostatin-1 (Fer-1) obviously alleviated ferroptosis-related changes in HG-cultured 661W cells and in retinal photoreceptor cells in diabetic mice. Taken together, our findings suggest that ferroptosis is involved in photoreceptor degeneration in the development of the early stages of DR.
- 29 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16946
Open AccessInhibition of Ferroptosis Ameliorates Photoreceptor Degeneration in Experimental Diabetic Mice
Diabetic retinopathy (DR) is a leading cause of vision impairment in the working-age population worldwide. Various modes of photoreceptor cell death contribute to the development of DR, including apoptosis and autophagy. However, whether ferroptosis is involved in the pathogenesis of photoreceptor degeneration in DR is still unclear. High-glucose (HG)-stimulated 661W cells and diabetic mice models were used for in vitro and in vivo experiments, respectively. The levels of intracellular iron, glutathione (GSH), reactive oxygen species (ROS), lipid peroxidation (MDA), and ferroptosis-related proteins (GPX4, SLC7A11, ACSL4, FTH1, and NCOA4) were quantified to indicate ferroptosis. The effect of ferroptosis inhibition was also assessed. Our data showed the levels of iron, ROS, and MDA were enhanced and GSH concentration was reduced in HG-induced 661W cells and diabetic retinas. The expression of GPX4 and SLC7A11 was downregulated, while the expression of ACSL4, FTH1, and NCOA4 was upregulated in the 661W cells cultured under HG conditions and in the photoreceptor cells in diabetic mice. Furthermore, the administration of the ferroptosis inhibitor ferrostatin-1 (Fer-1) obviously alleviated ferroptosis-related changes in HG-cultured 661W cells and in retinal photoreceptor cells in diabetic mice. Taken together, our findings suggest that ferroptosis is involved in photoreceptor degeneration in the development of the early stages of DR.